Merck (NYSE: MRK)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Merck Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Merck Company Info
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
News & Analysis
Commercial real estate stocks offer opportunities to get involved with some of the most interesting businesses in the world.
Earnings season is approaching its peak.
It's a risky deal for Merck, but it could pay off significantly.
Merck's move into immunology is a risky proposition.
Each is benefiting from recent good news, but there's also a theme-based tailwind brewing that could last a while.
Learn about some of the leading cancer stocks in the U.S stock market this year.
This company defied the bear market with impunity.
Valuation
Podcast Episodes
These healthcare stocks crushed the S&P 500's return last year, but that doesn't guarantee they'll be top performers in 2019.
From a big-time patent settlement between Merck & Co. and Bristol-Myers Squibb, to Johnson & Johnson's earnings, to Aetna and Humana's $37 billion merger bust, we dive into the details behind last week's biggest healthcare stories.
Merck, Gilead Sciences, and Ionis get a verdict in their patent suit, and Congress calls for a patent review of Medivation's Xtandi.
Earnings Transcripts
MRK earnings call for the period ending March 31, 2023.
MRK earnings call for the period ending December 31, 2022.
MRK earnings call for the period ending September 30, 2022.
MRK earnings call for the period ending June 30, 2022.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.